New research indicates that individuals who discontinue blockbuster GLP-1 drugs like semaglutide or tirzepatide may regain shed pounds at a significantly accelerated pace than those who end conventional diet and exercise regimens.
Findings released in a major health publication shows that while obese people frequently drop about a fifth of their body weight while on the medication, the weight returns at an average rate of 0.8 kg per month once they quit.
"Users using these treatments need to be informed of the danger of quick rebound weight gain when the medication concludes," cautioned lead investigator Dr. Susan Jebb.
That rate of regain suggests a reversion to original mass in about one and a half years.
Comparing Treatments
The analysis, which looked at dozens of studies involving over 9,000 of participants, contrasted the results of the injectable medications with older methods.
Researchers note that people who shed pounds through dieting generally see a more gradual weight regain—approximately 100 grams monthly—once they finish.
The Reason for the Quick Rebound
Experts believe the mechanism of the jabs accounts for the amplified rebound.
These medications imitate a natural hormone called glucagon-like peptide-1, which controls appetite.
"Sustained high doses of GLP-1 concentrations far above than normal could lead to the body to produce less of its endogenous GLP-1, and may also lessen sensitivity to its effects," said Dr. Adam Collins, a dietetics expert.
"Stopping of this GLP-1 'fix' results in appetite is unsuppressed, making binge eating much more probable."
A Lifelong Issue?
Health authorities suggest the injections for individuals with weight-linked medical conditions, accompanied by prescribed lifestyle changes.
Many experts argue that, considering the high risk of weight regain, the therapy is often long-term.
This opinion is echoed by drug manufacturers, who note that the results "highlight the chronic nature of excess weight," comparing it to managing conditions like high blood pressure.
Patient Testimonies
Users who have come off the medication explain a intense resurgence of hunger.
"It felt as if a trigger activating and I was suddenly extremely hungry," said one woman.
The struggle is worsened if individuals have not established lasting dietary or behavioural changes during therapy.
Widespread Interest
Survey data indicate that millions of people in the UK have tried weight-loss jabs in the last 12 months, with demand continuing to grow.
- Use is higher among females than males.
- The middle-aged age group shows the greatest usage rates.
- Many access the medications through private prescriptions rather than the NHS.
Finally, clinicians stress that while the jabs are powerful agents for weight loss, they are not a standalone cure and long-term success relies on combined behavioural support.
